DMAC

+ Watchlist + Portfolio

DiaMedica Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.81
52-Week Range: $5.14 – $10.42
Market Cap: $351.60M
P/E (TTM): —
EPS (TTM): -0.72
Dividend Yield: —

Advanced Metrics

Price/Book: 9.17
PEG Ratio: —
Return on Equity: -114.61%
Return on Assets: -64.12%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.72
Debt/Equity: 0.00
Total Debt: $185.00K
Free Cash Flow: $-17.65M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $323.92M

DMAC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.84M	$13.11M	$19.06M	$24.61M
Selling, General & Admin	$6.16M	$8.16M	$7.62M	$9.78M
Operating Expenses	$14.00M	$21.27M	$26.68M	$34.40M
Operating Income	-$14.00M	-$21.27M	-$26.68M	-$34.40M
EBITDA	-$13.98M	-$21.24M	-$26.64M	-$34.35M
Pretax Income	-$13.65M	-$19.34M	-$24.41M	-$32.74M
Income Tax	$28.00K	$43.00K	$30.00K	$28.00K
Net Income	-$13.68M	-$19.38M	-$24.44M	-$32.77M
Diluted EPS	-0.52	-0.60	-0.60	-0.70
Diluted Shares	26.44M	32.57M	40.40M	46.98M

DMAC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.73M	$4.54M	$3.02M	$15.65M
Receivables	$82.00K	$369.00K	$236.00K	$258.00K
Current Assets	$33.84M	$53.67M	$44.61M	$60.63M
Total Assets	$34.40M	$54.16M	$46.34M	$61.37M
Current Liabilities	$2.17M	$2.79M	$5.39M	$5.13M
Total Debt	$469.00K	$400.00K	$340.00K	$240.00K
Total Liabilities	$2.57M	$3.10M	$5.63M	$5.26M
Retained Earnings	-$96.18M	-$115.56M	-$140.00M	-$172.77M
Shareholders' Equity	$31.83M	$51.06M	$40.72M	$56.11M
Working Capital	$31.67M	$50.89M	$39.22M	$55.50M

DMAC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.51M	-$18.73M	-$22.08M	-$29.06M
Capital Expenditure	-$81.00K	-$24.00K	-$25.00K	-$40.00K
Free Cash Flow	-$11.59M	-$18.75M	-$22.10M	-$29.10M
Depreciation & Amortisation	$25.00K	$30.00K	$39.00K	$43.00K
Stock-Based Compensation	$1.50M	$1.68M	$2.08M	$3.85M
Investing Cash Flow	$11.54M	-$18.30M	$8.56M	-$2.19M
Financing Cash Flow	-$6.00K	$36.84M	$11.99M	$43.88M
Net Change in Cash	$21.00K	-$185.00K	-$1.52M	$12.62M

DMAC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.66M	$5.82M	$6.44M	$6.70M	$7.99M
Selling, General & Admin	$2.49M	$2.19M	$2.60M	$2.51M	$2.50M
Operating Expenses	$8.14M	$8.01M	$9.03M	$9.21M	$10.48M
Operating Income	-$8.14M	-$8.01M	-$9.03M	-$9.21M	-$10.48M
EBITDA	-$8.13M	-$8.00M	-$9.02M	-$9.20M	-$10.47M
Pretax Income	-$7.70M	-$7.69M	-$8.61M	-$8.73M	-$10.04M
Income Tax	$6.00K	$6.00K	$6.00K	$10.00K	$7.00K
Net Income	-$7.71M	-$7.70M	-$8.62M	-$8.74M	-$10.04M
Diluted EPS	-0.18	-0.18	-0.17	—	-0.19
Diluted Shares	42.84M	42.96M	49.63M	—	53.79M

DMAC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.59M	$4.11M	$3.33M	$15.65M	$4.87M
Receivables	$253.00K	$161.00K	$260.00K	$258.00K	$301.00K
Current Assets	$37.42M	$31.08M	$56.22M	$60.63M	$52.36M
Total Assets	$38.83M	$31.47M	$57.05M	$61.37M	$53.08M
Current Liabilities	$4.67M	$4.12M	$5.27M	$5.13M	$5.75M
Total Debt	$316.00K	$292.00K	$266.00K	$240.00K	$212.00K
Total Liabilities	$4.88M	$4.30M	$5.42M	$5.26M	$5.84M
Retained Earnings	-$147.71M	-$155.41M	-$164.03M	-$172.77M	-$182.81M
Shareholders' Equity	$33.95M	$27.17M	$51.62M	$56.11M	$47.23M
Working Capital	$32.76M	$26.96M	$50.95M	$55.50M	$46.62M

DMAC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.15M	-$7.60M	-$6.55M	-$7.76M	-$9.08M
Capital Expenditure	-$12.00K	-$6.00K	-$16.00K	-$6.00K	-$8.00K
Free Cash Flow	-$7.16M	-$7.60M	-$6.57M	-$7.77M	-$9.09M
Depreciation & Amortisation	$11.00K	$3.00K	$18.00K	$11.00K	$11.00K
Stock-Based Compensation	$867.00K	$771.00K	$1.02M	$1.19M	$822.00K
Investing Cash Flow	$6.62M	$8.96M	-$25.77M	$8.00M	-$2.11M
Financing Cash Flow	$91.00K	$161.00K	$31.53M	$12.09M	$417.00K
Net Change in Cash	-$436.00K	$1.52M	-$783.00K	$12.32M	-$10.78M

Market Snapshot

About

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for neurological and kidney diseases. The company's lead product candidate, DM199, is a recombinant human tissue kallikrein-1 protein being studied for acute ischemic stroke and chronic kidney disease. DiaMedica focuses on leveraging the therapeutic properties of the kallikrein-kinin system. The company conducts clinical trials and preclinical research while seeking regulatory approval pathways for its drug candidates.